Ruxolitinib
别名: INCB018424
中文名称:鲁索替尼
目录号:S1378 Purity: 99.98%
Ruxolitinib是第一个应用于临床的,有效的,选择性JAK1/2抑制剂,在无细胞试验中IC50为3.3 nM/2.8 nM。作用于JAK1, JAK2与作用于JAK3相比,选择性高130多倍。Ruxolitinib 通过毒性线粒体自噬杀死肿瘤细胞。Ruxolitinib 可诱导自噬并增强细胞凋亡。
CAS: 941678-49-5
客户使用Selleck的Ruxolitinib发表文献586篇
- Mol Cancer, 2023 10.1186/s12943-023-01837-4
- Cell Stem Cell, 2023 30(10):1382-1391.e5
- Cancer Cell, 2022 40(10):1128-1144.e8
- Sci Immunol, 2022 7(68):eabf2846
- Blood, 2022 blood.2021014304
- Blood, 2022 blood.2021012366
- Cancer Cell, 2021 S1535-6108(21)00492-X
- Cancer Cell, 2021 39-9:1214-1226.e10
- Cancer Discov, 2021 candisc.0694.2021
- Sci Immunol, 2021 6(59)eabi9007
- Nature, 2020 10.1038/s41586-020-2968-3
- Cancer Cell, 2020 38(3):412-423.e9
- Cancer Cell, 2020 13;37(1):104-122e12
- Cancer Cell, 2020 38(6):872-890.e6
- Immunity, 2020 S1074-7613(20)30313-7
- Cell Host Microbe, 2020 11;27(3):476-485 e7
- Gastroenterology, 2020 158(5):1417-1432.e11
- Cancer Discov, 2020 10(4):608-625
- Blood, 2020 135(9):668-679
- Blood, 2020 10.1182/blood.2019004332
- Blood, 2020 12;blood.2020006075
- Nat Med, 2019 25(1):95-102
- Cancer Cell, 2019 36(2):179-193
- Nat Microbiol, 2019 4(2):339-351
- Cancer Discov, 2019 9(1):34-45
- Cancer Discov, 2019 9(6):756-777
- Cell Stem Cell, 2019 25(1):69-86
- Nat Cell Biol, 2019 21(6):778-790
- Blood, 2019 134(11):867-879
- Blood, 2019 134(19):1670-1682
- Blood, 2019 26;134(26):2388-2398
- Blood, 2019 10.1182/blood.2018864173
- Cell, 2018 175(2):458-471
- Cancer Cell, 2018 34(2):298-314
- Cancer Cell, 2018 34(3):439-452
- Immunity, 2018 48(4):787-798
- Immunity, 2018 49(4):780-781
- Nat Med, 2017 23(3):291-300
- Cell, 2017 168(6):1053-1064
- Cell, 2017 168(5):890-903
- Cell, 2017 171(1):217-228
- Nat Mater, 2017 16(12):1252-1261
- Immunity, 2017 20;46(6):992-1004.e5
- Immunity, 2017 21;46(2):220-232
- Immunity, 2017 47(6):1083-1099.e6
- Blood, 2017 130(26):2848-2859
- Blood, 2017 129(2):199-208
- Blood, 2017 129(14):1969-1979
- Nature, 2016 529(7586):413-417
- Gastroenterology, 2016 151(1):180-193
- Cell Stem Cell, 2016 19(6):738-751
- Blood, 2016 127(13):1666-75
- Nat Med, 2015 10.1038/nm.4013
- Nat Med, 2015 21(9):1038-47
- Cancer Cell, 2015 28(1):29-41
- Nat Cell Biol, 2015 17(1):57-67
- Blood, 2014 123(24):3832-42
- Blood, 2013 15;122(7):1192-202
- Nat Commun, 2024 15(1):2503
- Nat Commun, 2024 15(1):8663
- Nat Commun, 2024 15(1):2989
- Nat Commun, 2024 15(1):7885
- Blood Cancer J, 2024 14(1):207
- Acta Neuropathol, 2024 147(1):28
- Theranostics, 2024 14(3):1224-1240
- J Exp Clin Cancer Res, 2024 43(1):64
- EMBO Mol Med, 2024 16(4):904-926
- J Biomed Sci, 2024 31(1):51
- J Neuroinflammation, 2024 21(1):236
- Cell Death Dis, 2024 15(9):683
- Cell Rep, 2024 43(2):113600.
- Cell Rep, 2024 43(6):114310
- EMBO Rep, 2024 25(5):2188-2201
- EMBO Rep, 2024 10.1038/s44319-024-00346-9
- EMBO Rep, 2024 25(3):1106-1129
- Antiviral Res, 2024 222:105811
- Breast Cancer Res, 2024 26(1):167
- iScience, 2024 27(3):109213
- Front Pharmacol, 2024 15:1375421
- Front Cell Dev Biol, 2024 12:1302141
- J Virol, 2024 98(10):e0105524
- J Cell Mol Med, 2024 28(20):e70138
- Transl Oncol, 2024 44:101939
- Antimicrob Agents Chemother, 2024 68(4):e0135023.
- Neoplasia, 2024 58:101065
- J Biol Chem, 2024 301(1):108070
- Viruses, 2024 16(4)646
- Eur J Pharm Sci, 2024 197:106767
- Sci Rep, 2024 14(1):2810
- Molecules, 2024 29(8)1801
- BMC Biotechnol, 2024 24(1):91
- J Virol Methods, 2024 323:114854
- Cancer Genomics Proteomics, 2024 21(5):511-522
- Nagoya J Med Sci, 2024 86(2):326-332
- Genes Chromosomes Cancer, 2024 63(1):e23217
- bioRxiv, 2024 2024.01.27.577579
- Nat Commun, 2023 10.1038/s41467-023-42978-w
- Nat Commun, 2023 14(1):7161
- Nat Commun, 2023 14(1):8048
- Nat Commun, 2023 14(1):5818
- Mol Cell, 2023 10.1016/j.molcel.2023.10.008
- J Clin Invest, 2023 133(3)e125986
- Blood Cancer J, 2023 13(1):106
- Am J Hematol, 2023 98(7):1029-1042
- J Med Virol, 2023 95(2):e28478
- Clin Cancer Res, 2023 29(5):943-956
- J Exp Clin Cancer Res, 2023 10.1186/s13046-023-02872-1
- Cell Death Dis, 2023 14(7):463
- Cell Rep, 2023 42(5):112438
- Cell Rep, 2023 42(6):112547
- Blood Adv, 2023 7(24):7445-7456
- Front Immunol, 2023 10.3389/fimmu.2023.1190261
- Front Immunol, 2023 14:1078958
- Front Immunol, 2023 10.3389/fimmu.2023.1263926
- Cell Death Discov, 2023 9(1):374
- Mol Oncol, 2023 17(6):1112-1128
- mBio, 2023 14(4):e0119423
- Int J Mol Sci, 2023 24(14)11727
- Cells, 2023 12(4)598
- iScience, 2023 26(4):106309
- Mol Cancer Ther, 2023 22(1):135-149
- Front Cell Infect Microbiol, 2023 13:1222805
- Int J Mol Sci, 2023 24(9)7730
- Int J Mol Sci, 2023 24(7)6228
- Rheumatology (Oxford), 2023 kead001
- J Virol, 2023 97(6):e0040023
- Cancers (Basel), 2023 16(1)9
- Cancers (Basel), 2023 15(16)4141
- Front Oncol, 2023 13:1043694
- World J Stem Cells, 2023 15(8):787-806
- J Ovarian Res, 2023 16(1):229
- Redox Rep, 2023 28(1):2152607
- PLoS One, 2023 18(2):e0277318
- Virology, 2023 582:114-127
- Ann Hematol, 2023 10.1007/s00277-023-05520-y
- Adv Skin Wound Care, 2023 36(5):249-258
- Cancer Res Commun, 2023 3(4):592-606
- bioRxiv, 2023 2023.07.12.548716
- bioRxiv, 2023 2023.09.19.558507
- Sci Transl Med, 2022 14(654):eabo5254
- Nat Commun, 2022 13(1):6226
- Nat Commun, 2022 13(1):5545
- Nat Commun, 2022 13(1):2256
- Neuron, 2022 S0896-6273(22)00807-8
- Adv Sci (Weinh), 2022 10.1002/advs.202104055
- Mol Neurodegener, 2022 17(1):7
- J Allergy Clin Immunol, 2022 S0091-6749(22)01055-7
- Am J Hematol, 2022 97(4):390-400
- Leukemia, 2022 36(7):1843-1849
- J Exp Clin Cancer Res, 2022 41(1):10
- Cancer Res, 2022 82(9):1774-1788
- Cancer Res, 2022 CAN-22-0770
- J Immunother Cancer, 2022 10(1)e003766
- J Immunother Cancer, 2022 10(6)e003863
- Cancer Immunol Res, 2022 canimm.0643.2021
- BMC Med, 2022 20(1):187
- J Clin Immunol, 2022 10.1007/s10875-022-01273-x
- Cell Rep, 2022 39(2):110650
- JCI Insight, 2022 e150363
- JCI Insight, 2022 7(24)e150849
- JCI Insight, 2022 e156330
- NPJ Precis Oncol, 2022 6(1):11
- EMBO Rep, 2022 10.15252/embr.202152904
- EMBO Rep, 2022 23(8):e54438
- Front Immunol, 2022 13:1001068
- Front Immunol, 2022 13:955038
- Front Immunol, 2022 13:960544
- Front Immunol, 2022 13:832263
- Sci Signal, 2022 15(744):eabn7082
- Cell Mol Gastroenterol Hepatol, 2022 13(6):1673-1699
- Mol Oncol, 2022 16(20):3606-3619
- mBio, 2022 e0105522
- mBio, 2022 13(3):e0085422
- Cells, 2022 11(17)2644
- Cells, 2022 11(3)381
- Cells, 2022 11(24)3983
- Commun Biol, 2022 5(1):1066
- iScience, 2022 25(10):105182
- Biochem Pharmacol, 2022 197:114940
- Front Pharmacol, 2022 13:896167
- Front Pharmacol, 2022 13:1032975
- Int J Mol Sci, 2022 23(5)2535
- Int J Mol Sci, 2022 23(17)9587
- Virol Sin, 2022 S1995-820X(22)00080-3
- J Virol, 2022 96(15):e0187421
- J Cell Mol Med, 2022 26(23):5858-5871
- Cancers (Basel), 2022 14(21)5215
- Cancers (Basel), 2022 14(19)4883
- Cancers (Basel), 2022 14(19)4675
- J Pers Med, 2022 12(2)258
- J Biol Chem, 2022 S0021-9258(22)00796-7
- Front Oncol, 2022 12:816894
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Pigment Cell Melanoma Res, 2022 35(3):342-355
- Dis Model Mech, 2022 15(5)dmm049088
- Pathogens, 2022 11(8)853
- PLoS One, 2022 17(4):e0266412
- Dis Markers, 2022 2022:4253566
- Exp Mol Pathol, 2022 S0014-4800(21)00139-8
- Exp Dermatol, 2022 10.1111/exd.14566
- Genes Cells, 2022 10.1111/gtc.12940
- Sci Adv, 2022 8(4):eabi7711
- Sci Adv, 2022 8(29):eabm8780
- PNAS Nexus, 2022 1(2):pgac067
- Nat Commun, 2021 12(1):7268
- Nat Commun, 2021 12(1):4566
- Mol Cell, 2021 S1097-2765(21)01068-6
- Nucleic Acids Res, 2021 49(22):12706-12715
- Leukemia, 2021 10.1038/s41375-021-01326-x
- J Exp Clin Cancer Res, 2021 40(1):297
- Cancer Res, 2021 canres.3761.2020
- Cancer Immunol Res, 2021 9(10):1187-1201
- Cancer Immunol Res, 2021 9-5:542-553
- PLoS Biol, 2021 19(12):e3001065
- Cancer Lett, 2021 510:37-47
- Cancer Lett, 2021 507:26-38
- Cell Death Dis, 2021 12(10):864
- Cell Rep, 2021 34(11):108870
- Br J Cancer, 2021 10.1038/s41416-021-01270-8
- Am J Transplant, 2021 21(7):2360-2371
- Cell Rep, 2021 34(3):108627
- JCI Insight, 2021 6(7)142205
- Cell Mol Life Sci, 2021 10.1007/s00018-021-03997-2
- NPJ Precis Oncol, 2021 5(1):75
- J Cell Biol, 2021 220(9)e202004114
- Front Immunol, 2021 12:749094
- Hemasphere, 2021 5(7):e593
- J Invest Dermatol, 2021 S0022-202X(21)02350-2
- Br J Haematol, 2021 10.1111/bjh.17910
- mBio, 2021 12(6):e0322821
- Front Cell Infect Microbiol, 2021 11:689707
- Int J Mol Sci, 2021 22(3)1194
- Int J Mol Sci, 2021 22(7)3530
- Front Cell Dev Biol, 2021 9:643043
- Front Cell Dev Biol, 2021 9:695225
- Front Cell Dev Biol, 2021 9:647713
- J Virol, 2021 JVI0086221
- Oncotarget, 2021 12(9):878-890
- J Cell Mol Med, 2021 10.1111/jcmm.16684
- NPJ Genom Med, 2021 6(1):34
- Aging (Albany NY), 2021 13(10):14234-14257
- Cancers (Basel), 2021 13(15)3780
- Eur J Pharmacol, 2021 902:174121
- Eur J Pharmacol, 2021 S0014-2999(21)00845-1
- Bioengineered, 2021 12(2):12800-12811
- FASEB J, 2021 35(4):e21437
- Neoplasia, 2021 23(2):270-279
- Viruses, 2021 13(7)1227
- Viruses, 2021 13(7)1406
- Viruses, 2021 13(2)154
- Viruses, 2021 13-102017
- Ann Transl Med, 2021 9(18):1441
- Sci Rep, 2021 11(1):11234
- Sci Rep, 2021 11(1):10093
- Pharmaceuticals (Basel), 2021 14(11)1081
- Microorganisms, 2021 9(3)564
- J Immunol, 2021 ji2000569
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- J Pathol Clin Res, 2021 10.1002/cjp2.211
- J Gen Virol, 2021 102(11)
- J Gen Virol, 2021 102(3)
- PLoS One, 2021 16(3):e0248175
- Hum Mol Genet, 2021 ddab035
- J Immunotoxicol, 2021 18(1):154-162
- Exp Hematol, 2021 S0301-472X(21)00089-8
- Exp Hematol, 2021 S0301-472X(21)00244-7
- Sci Adv, 2021 7(50):eabl5182
- Sci Adv, 2021 7(7)eabb3555
- J Biomed Res, 2021 35(6):448-458
- B.S., The University of Arizona, 2021
- Nat Commun, 2020 11(1):4886
- Nat Commun, 2020 11(1):6211
- J Clin Invest, 2020 130(2):863-876
- J Clin Invest, 2020 19 pii: 134424
- Hepatology, 2020 25
- Mol Ther, 2020 S1525-0016(20)30609-2
- Dev Cell, 2020 S1534-5807(20)30980-1
- EMBO J, 2020 e103922
- Leukemia, 2020 10.1038/s41375-020-01077-1
- Cancer Res, 2020 10.1158/0008-5472.CAN-19-3183
- Proc Natl Acad Sci U S A, 2020 117(26):15047-15054
- Proc Natl Acad Sci U S A, 2020 29;201918307
- Int J Biol Sci, 2020 16(2):194-203
- Cell Rep, 2020 33(1):108211
- JCI Insight, 2020 5(4)
- Oncogene, 2020 39(15):3163-3178
- Oncogene, 2020 39(31):5323-5337
- Phytomedicine, 2020 80:153394
- Blood Adv, 2020 4(5):819-829
- Stem Cell Res Ther, 2020 11(1):67
- Blood Adv, 2020 4(20):5297-5310
- Front Immunol, 2020 11:344
- Front Immunol, 2020 11:1114
- Cell Death Discov, 2020 2;6:42
- PLoS Pathog, 2020 16;16(3):e1008341
- Hemasphere, 2020 4(6):e497
- Am J Respir Cell Mol Biol, 2020 10.1165/rcmb.2019-0431OC
- mBio, 2020 11(2)
- Comput Struct Biotechnol J, 2020 18:3977-3986
- Cancer Cell Int, 2020 19;20:58
- J Cell Physiol, 2020 235(5):4605-4617
- Int J Mol Sci, 2020 21(3)
- J Virol, 2020 15 pii: JVI
- J Virol, 2020 94(2)
- J Virol, 2020 JVI.01413-20
- J Virol, 2020 17;94(3) pii: e01233-19
- J Cell Mol Med, 2020 10.1111/jcmm.15700
- J Cell Mol Med, 2020 10.1111/jcmm.16132
- J Cell Mol Med, 2020 24(5):2981-2992
- Cancers (Basel), 2020 12(6):E1603
- Cancers (Basel), 2020 12(9)E2586
- Aging (Albany NY), 2020 12
- Am J Physiol Lung Cell Mol Physiol, 2020 318(5):L864-L872
- FASEB J, 2020 10.1096/fj.201902793RR
- mSphere, 2020 5(6)e00449-20
- Neoplasia, 2020 22(10):470-483
- J Biol Chem, 2020 jbc.AC120.13788
- Viruses, 2020 12(3)
- Carcinogenesis, 2020 41(7):993-1004
- Viruses, 2020 12(10)E1141
- J Immunol, 2020 1;204(9):2492-2502
- J Immunol, 2020 205(10):2629-2639
- Invest Ophthalmol Vis Sci, 2020 61(14):24
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- J Endocrinol, 2020 245(1):141-153
- PLoS Negl Trop Dis, 2020 14(9):e0008610
- Virology, 2020 551:75-83
- Exp Eye Res, 2020 S0014-4835(20)30611-4
- Cancer Manag Res, 2020 12:703-717
- BMC Mol Cell Biol, 2020 21(1):74
- J Interferon Cytokine Res, 2020 40(2):92-105
- Cancer Drug Resist, 2020 3(3):603-612
- bioRxiv, 2020 2020.10.27.358259
- Biochem Biophys Rep, 2020 24:100832
- Biochem Biophys Rep, 2020 24:100838
- Nat Commun, 2019 10(1):2764
- J Clin Invest, 2019 129(3):1193-1210
- J Allergy Clin Immunol, 2019 143(2):700-711
- Cytokine Growth Factor Rev, 2019 47:62-73
- Leukemia, 2019 33(6):1373-1386
- Leukemia, 2019 33(5):1243-1255
- Leukemia, 2019 10.1038/s41375-019-0381-4
- J Exp Clin Cancer Res, 2019 18;38(1):85
- J Exp Clin Cancer Res, 2019 38(1):322
- Cancer Res, 2019 10.1158/0008-5472.CAN-19-0596
- EMBO Mol Med, 2019 11(10):e9930
- Cancer Immunol Res, 2019 7(9):1457-1471
- Cancer Immunol Res, 2019
- Haematologica, 2019 104(6):1209-1220
- Haematologica, 2019 104(7):e288-e292
- Cancer Lett, 2019 459:86-99
- Cell Death Dis, 2019 10(9):649
- Cell Rep, 2019 29(4):860-872
- Br J Cancer, 2019 121(7):567-577
- Cell Commun Signal, 2019 17(1):46
- Blood Adv, 2019 3(9):1499-1511
- Stem Cell Res Ther, 2019 10(1):91
- Stem Cell Res Ther, 2019 10(1):210
- Blood Adv, 2019 3(7):1061-1072
- J Microbiol Immunol Infect, 2019 10.1016/j.jmii.2019.05.008
- Front Immunol, 2019 10:1659
- Front Immunol, 2019 1.1243055556
- Front Immunol, 2019 1.4118055556
- NPJ Regen Med, 2019 0.16805555556
- PLoS Pathog, 2019 15(3):e1007667
- Inflamm Res, 2019 10.1007/s00011-019-01293-1
- Int J Cancer, 2019 10.1002/ijc.32123
- mBio, 2019 10(5)
- iScience, 2019 19:647-661
- Int J Mol Sci, 2019 20(13)
- J Cell Physiol, 2019 234(12):22260-22271
- J Virol, 2019 94(1)
- J Virol, 2019 93(4)
- J Virol, 2019 93(18)
- Oncotarget, 2019 10(56):5755-5767
- Exp Neurol, 2019 317:226-243
- J Cell Mol Med, 2019 23(6):4301-4312
- Cancers (Basel), 2019 11(9)
- Cancers (Basel), 2019 11(4)
- J Biol Chem, 2019 294(32):11952-11959
- Front Oncol, 2019 9:1070
- Mediators Inflamm, 2019 2019:3738409
- Sci Rep, 2019
- Sci Rep, 2019 9(1):16379
- J Immunol, 2019 202(4):1124-1136
- Invest Ophthalmol Vis Sci, 2019 60(12):3776-3785
- Immunol Lett, 2019 216:43-50
- Life Sci Alliance, 2019 2(5)
- Mol Cell Biochem, 2019 462(1-2):41-50
- Oncol Rep, 2019 41(1):437-446
- BMC Cancer, 2019 19(1):936
- PLoS One, 2019 14(7):e0220026
- PLoS One, 2019 14(9):e0222944
- Invest New Drugs, 2019 10.1007/s10637-019-00853-w
- Biochem Biophys Res Commun, 2019 513(3):714-720
- Curr Cancer Drug Targets, 2019 19(7):571-582
- Evid Based Complement Alternat Med, 2019 2019:3909468
- Immunotherapy, 2019 11(6):483-496
- Zhonghua Xue Ye Xue Za Zhi, 2019 40(12):1003-1007
- Sci Transl Med, 2018 10(436)
- Nat Commun, 2018 9(1):2024
- Nat Commun, 2018 9(1):1485
- J Clin Invest, 2018 128(1):387-401
- J Exp Med, 2018 215(10):2600-2616
- Nat Chem Biol, 2018 14(3):291-298
- Brain, 2018 141(6):1609-1621
- J Allergy Clin Immunol, 2018 142(1):328-330
- J Allergy Clin Immunol, 2018 141(6):2142-2155.e5
- Leukemia, 2018 32(11):2483-2494
- Leukemia, 2018 32(11):2374-2387
- Leukemia, 2018 32(1):184-193
- Cancer Res, 2018 78(2):436-450
- Cancer Res, 2018 78(24):6762-6770
- Cancer Res, 2018 78(1):75-87
- Proc Natl Acad Sci U S A, 2018 115(42):E9869-E9878
- EBioMedicine, 2018 36:367-375
- Haematologica, 2018 10.3324/haematol.2018.189399
- Cancer Lett, 2018 412:194-207
- Cell Death Dis, 2018 9(9):855
- Cell Rep, 2018
- Cell Rep, 2018 24(8):2155-2166
- JCI Insight, 2018 3(18)
- Oncogene, 2018 37(8):1107-1118
- Blood Adv, 2018 2(23):3428-3442
- Oxid Med Cell Longev, 2018 2018:3824509
- Front Immunol, 2018 9:737
- Front Immunol, 2018 9:1051
- Oncoimmunology, 2018 7(9):e1480286
- Cell Mol Gastroenterol Hepatol, 2018 7(1):55-71
- Oncoimmunology, 2018
- PLoS Pathog, 2018 14(10):e1007358
- Br J Haematol, 2018 183(3):428-444
- Int J Cancer, 2018 10.1002/ijc.32081
- Cancer Immunol Immunother, 2018 67(2):271-283
- Front Cell Infect Microbiol, 2018 8:312
- Mol Cancer Ther, 2018 17(12):2796-2810
- Mol Cancer Ther, 2018 17(4):732-739
- J Cell Physiol, 2018 233(1):422-433
- Am J Physiol Cell Physiol, 2018 314(5):C589-C602
- J Virol, 2018 92(5)e01875-17
- Pharmaceutics, 2018 10(4)
- Oncotarget, 2018
- Oncotarget, 2018 9(9):8560-8572
- Cancers (Basel), 2018 10(12)
- Transl Oncol, 2018 11(6):1406-1418
- Eur J Pharmacol, 2018 825:28-33
- mSphere, 2018 3(1)e00567-17
- Molecules, 2018 23(6)
- Sci Rep, 2018 8(1):13638
- JCO Precis Oncol, 2018 2018
- J Immunol, 2018 201(8):2462-2471
- J Immunol, 2018 201(8):2392-2402
- J Cell Sci, 2018 131(10)
- Cancer Med, 2018 10.1002/cam4.1524
- Drug Metab Dispos, 2018 46(2):131-140
- Endocr Relat Cancer, 2018 25(4):471-480
- Cytokine, 2018 111:209-215
- PLoS One, 2018 13(2):e0193429
- Ann Surg Oncol, 2018 25(8):2449-2456
- SLAS Discov, 2018 23(7):687-696
- Biochem Biophys Res Commun, 2018 495(1):1534-1540
- Eur J Haematol, 2018 101(1):57-67
- Leuk Res Rep, 2018 9:38-41
- Nat Commun, 2017 8:15289
- Neuron, 2017 96(6):1290-1302
- Nucleic Acids Res, 2017 45(20):11622-11642
- Nat Chem Biol, 2017 13(1):38-45
- J Allergy Clin Immunol, 2017 139(5):1629-1640
- Blood Cancer J, 2017 7(6):e572
- Acta Neuropathol, 2017 134(6):905-922
- Leukemia, 2017 31(12):2568-2576
- EMBO J, 2017 36(5):604-616
- Cancer Res, 2017 77(13):3502-3512
- Cancer Res, 2017 77(18):5142-5157
- Proc Natl Acad Sci U S A, 2017 114(20):E4030-E4039
- EBioMedicine, 2017 15:24-35
- Proc Natl Acad Sci U S A, 2017 114(6):E980-E989
- Cancer Immunol Res, 2017 5(8):695-709
- Cancer Lett, 2017 403:206-215
- Elife, 2017 6e27210
- Blood Adv, 2017 1(20):1635-1644
- Cell Biosci, 2017 7:43
- Osteoarthritis Cartilage, 2017 25(9):1505-1515
- PLoS Pathog, 2017 13(12):e1006740
- Arch Toxicol, 2017 91(10):3385-3402
- Clin Exp Allergy, 2017 47(1):71-84
- Arch Toxicol, 2017 91(8):2921-2938
- Clin Epigenetics, 2017 9:4
- Oncotarget, 2017 8(53):91516-91529
- Oncotarget, 2017 8(52):90262-90277
- Oncotarget, 2017 8(52):89923-89938
- Antimicrob Agents Chemother, 2017 61(10)e00771-17
- J Biol Chem, 2017 292(35):14381-14390
- FASEB J, 2017 31(5):1903-1915
- J Biol Chem, 2017 292(20):8136-8148
- mSphere, 2017 2(3)e00234-17
- Mol Ther Methods Clin Dev, 2017 7:60-73
- Sci Rep, 2017 7(1):1787
- Sci Rep, 2017 7:43441
- Eur J Pharm Sci, 2017 106:302-312
- J Inflamm Res, 2017 10:143-150
- Immunol Res, 2017 65(4):903-912
- Biol Reprod, 2017 96(3):542-550
- FEBS Lett, 2017 591(22):3709-3720
- Oncol Lett, 2017 13(1):497-505
- Sci Transl Med, 2016 8(334):334ra53
- J Clin Invest, 2016 126(4):1300-10
- PLoS Med, 2016 13(12):e1002200
- Clin Cancer Res, 2016 22(13):3328-39
- Leukemia, 2016 30(9):1832-43
- Cancer Res, 2016 76(4):773-86
- Cancer Res, 2016 76(5):1214-24
- Proc Natl Acad Sci U S A, 2016 113(6):1624-9
- Haematologica, 2016 101(10):1190-1199
- Oncogene, 2016 35(46):6001-6014
- Elife, 2016 5e16220
- J Med Chem, 2016 59(18):8233-62
- J Leukoc Biol, 2016 100(1):213-22
- Oncotarget, 2016 7(37):59260-59272
- Oncotarget, 2016 7(38):61601-61618
- Oncotarget, 2016 7(30):47465-47478
- Oncotarget, 2016 7(12):13886-901
- Oncotarget, 2016 7(45):72608-72621
- Stem Cells, 2016 34(4):1123-33
- Mol Cancer Res, 2016 14(5):482-92
- Am J Physiol Lung Cell Mol Physiol, 2016 311(2):L364-74
- J Biol Chem, 2016 291(49):25656-25666
- J Biol Chem, 2016 291(32):16686-98
- Sci Rep, 2016 6:27326
- J Interferon Cytokine Res, 2016 36(9):552-62
- MOL VIS, 2016 22:1122-1136
- Parasite Immunol, 2016 38(11):678-687
- Korean J Parasitol, 2016 54(2):123-32
- J Clin Invest, 2015 125(9):3667-80
- J Allergy Clin Immunol, 2015 135(2):551-3
- Cancer Res, 2015 10.1158/0008-5472.CAN-14-3198
- Cell Rep, 2015 11(1):98-110
- Transl Res, 2015 166(6):772-82
- Front Immunol, 2015 5:655
- Front. Immunol, 2015 Volume 5
- J Med Chem, 2015 58(16):6589-606
- Br J Haematol, 2015 10.1111/bjh.13448
- Biochem Pharmacol, 2015 10.1016/j.bcp.2015.04.019
- Oncotarget, 2015 6(37):40141-57
- Oncotarget, 2015
- Mol Nutr Food Res, 2015 59(11):2143-54
- Sci Rep, 2015 5:7820
- J Immunol, 2015 194(2):827-35
- J Immunol, 2015 194(2):553-9
- Cell Physiol Biochem, 2015 37(2):768-78
- Virology, 2015 485:340-54
- Cytometry A, 2015 10.1002/cyto.a.22628
- PLoS One, 2015 10(3):e0116723
- Virology, 2015 483:126-40
- Hum Pathol, 2015 46(2):284-94
- J Interferon Cytokine Res, 2015 35(9):698-709
- Blood Cells Mol Dis, 2015 55(3):241-7
- Leuk Res Rep, 2015 4(1):8-11
- Kidney Int, 2014 86(6):1187-96
- J Clin Invest, 2014 124(12):5263-74
- Gastric Cancer, 2014 10.1007/s10120-014-0444-1
- Sci Signal, 2014 7(322):ra38
- Apoptosis, 2014 19(11):1627-36
- Oncotarget, 2014 5(10):2947-61
- Oncotarget, 2014 5(16):6801-15
- Gene Ther, 2014 10.1038/gt.2014.83
- Antimicrob Agents Chemother, 2014 58(4):1977-86
- J Immunol, 2014 193(3):1142-50
- Cell Cycle, 2014 13(12):1958-69
- PLoS One, 2014 9(8):e103629
- PLoS One, 2014 9(10):e109799
- PLoS One, 2014 9(11):e112014
- J Pharm Biomed Anal, 2014 94:125-31
- Leuk Res, 2014 38(2):236-42
- Genes Cancer, 2014 5(11-12):470-9
- Cancer Lett, 2013 341(2):224-30
- Cancer Gene Ther, 2013 20(10):582-9
- J Immunol, 2013 191(7):3896-904
- PLoS One, 2013 8(9):e74257
- PLoS One, 2013 8(8): e74676
- Genes Dev, 2012 26(19):2144-53
- J Immunol, 2012 189(6):2784-92
- Universidad de Cantabria, 2012 García Díaz
化学信息&溶解度
分子量 | 306.37 |
分子式 | C17H18N6 |
CAS号 | 941678-49-5 |
Smiles | C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 144 mg/mL ( 470.01 mM; Ultrasonicated; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 12 mg/mL Water : Insoluble DMSO : 61 mg/mL ( 199.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 61 mg/mL Water : Insoluble DMSO : 61 mg/mL ( 199.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 31 mg/mL Water : Insoluble DMSO : 61 mg/mL ( 199.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 33 mg/mL Water : Insoluble DMSO : 61 mg/mL ( 199.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 30 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
95% Corn oil
浓度:3mg/ml
(9.79mM)
操作示例:以1 mL工作液为例,取 50 μL 60 mg/mL的澄清 DMSO 储备液加到 950 μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG 300
5%Tween80
50% ddH2O
浓度:3mg/ml
(9.79mM)
操作示例:以 1 mL 工作液为例,取50μL 60mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入 500 μLddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。